Slide 1: Investor Presentation Q2 FY 16 Earnings Release
Investor Presentation Q2 FY 16 Earnings Release 5 November 2015 Investor Presentation Q2 FY 16 Earnings Release Confidential 1
Slide 2: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results t
Slide 3: Business Update
Business Update In Q2, Cipla achieved revenue of Rs 3,452 crores; 24.8% growth vs. last year ▪ Excluding the one-offs, all business units had strong growth ▪ Domestic Rx business growth in line with the Industry growth (as per IMS); decline in domestic Gx business ▪ Export business growth of 52.3%;
Slide 4: Financial Performance Summary – Q2 FY 16
Financial Performance Summary – Q2 FY 16 Q2 FY 2015-16 Consolidated Actuals vs Q2 FY 15 vs Q1 FY16 (Rs Cr.) Income from 3,452 24.8% -10.4% Operations Domestic Revenue 1,262 0.9% -9.6% Exports Revenue 2,100 52.3% -11.8% EBITDA 789 41.4% -24% EBITDA % 22.9% 2.7% -4.1% PAT 431 44.4% -33.7% PAT % 12.5%
Slide 5: Financial Performance Summary – H1 FY 16
Financial Performance Summary – H1 FY 16 H1 FY 2015-16 Consolidated Actuals vs H1 FY 15 (Rs Cr.) Income from 7,305 33.1% Operations Domestic Revenue 2,659 4.7% Export Revenue 4,480 63.7% EBITDA 1,828 66.2% EBITDA % 25% 4.9% PAT 1,082 82.4% PAT % 14.8% 4.0% Investor Presentation Q2 FY 16 Earnings Rel
Slide 6: Performance Summary (1/3)
Performance Summary (1/3) Area Highlights • Consolidated H1 FY 2015-16 Revenue: Rs. 7,305 Cr, 33.1% above H1 FY 2014-15 • Consolidated H1 FY 2015-16 EBITDA: Rs. 1,828 Cr, 66.2% above H1 FY 2014-15 Financial • Consolidated H1 FY 2015-16 EBITDA margin: 25%, as compared to 20.1% in H1 FY 2014-15 Perfor
Slide 7: Performance Summary (2/3)
Performance Summary (2/3) Area Highlights Entered into a definitive agreement to acquire 100% stake in two US based companies, InvaGen Pharmaceutical Inc. and Exelan Pharmaceuticals Inc; transaction is expected to be completed by end of December 2015 Combined revenue of these companies was over
Slide 8: Performance Summary (3/3)
Performance Summary (3/3) Area Highlights Operational • Capacity enhancement initiatives on track Performance • New capacity build underway for ARV products – expected completion in H1 FY 2016-17 • >200 formulation development projects underway R&D Pipeline • Formulation filings: North America (4),